Lantheus Holdings, Inc. (LNTH) is a Massachusetts-based life sciences company that develops, manufactures, and sells diagnostic imaging agents and radiopharmaceuticals. Its flagship product, PYLARIFY, is a PSMA PET imaging agent used to detect prostate cancer, while DEFINITY supports cardiac ultrasound and Neuraceq aids Alzheimer's disease evaluation.
The $115 level matters because it sits at the intersection of Wall Street's most optimistic remaining price targets and the maximum value implied by the company's pending takeover. After the stock rallied more than 80% over the past year, attention has shifted from pure fundamentals to the mechanics of the Curium deal and whether shareholders can ultimately capture the full value on the table.
On August 3, 2026, Lantheus announced an agreement to be acquired by Curium US Holdings for $102.50 per share in cash, plus contingent value rights worth up to $12 per share tied to milestones expected around 2030. The transaction is anticipated to close in the first half of 2027, with an outside date of May 2, 2027.
This structure reframes the entire question. With the stock recently trading near $100.88 — slightly below the $102.50 cash offer — the modest discount reflects deal-completion risk, including potential antitrust review by the Federal Trade Commission (FTC). Because the headline consideration is fixed cash, the share price is no longer being driven primarily by earnings growth. Instead, it trades as a merger-arbitrage situation.
The clearest path to $115 runs through the CVRs. If the deal closes and the contingent milestone payments are valued near their full $12 per share, the combined consideration would total approximately $114.50. Analysts who still carry targets at or near $115 are effectively betting that the merger completes and that a meaningful portion of the CVR value is realized.
Supporting this view, Lantheus reported second-quarter earnings of $1.55 per share, well above the $1.30 consensus, on revenue of $388.18 million. PYLARIFY generated $240.4 million in quarterly revenue, and the company received FDA approval for PYLARIFY TruVu in March 2026, a new formulation expected to expand manufacturing reach and distribution flexibility. These commercial strengths underpin the strategic rationale for the acquisition and, by extension, confidence in the deal closing.
The principal challenge is structural: a cash deal at $102.50 does not naturally allow the stock to trade meaningfully above that level unless the CVRs are assigned substantial standalone value. Because CVR payouts depend on 2030 milestones, their present value is uncertain and heavily discounted by the market.
Deal risk is a further consideration. Product overlap between the two companies — including in neuroendocrine tumor imaging and PSMA-targeted agents — has drawn scrutiny, and B. Riley noted that Curium would not be required to accept remedies affecting its own assets. If regulators impose conditions or the transaction stalls, the stock could drift back toward its pre-deal fundamentals, well below $115.
Wall Street's view has converged around the deal economics. Following the announcement, multiple firms cut their targets to align with the acquisition terms: B. Riley downgraded the stock to Neutral with a $105.40 target, TD Cowen moved to Hold at $102.50, and Truist reduced its target to $103. A consensus estimate clusters near $106 to $111, while a small number of firms — including Citizens and Mizuho — have maintained more optimistic $115 targets. This split neatly captures the debate: the base-case cash offer sits near $102.50, while the higher targets depend on CVR upside.
From a technical perspective, the $102.50 deal price functions as a hard resistance level in the near term, and the stock's 52-week high of $111.86 now stands above any realistic pre-closing ceiling. On the downside, the $100 round-number zone and the $94–$95 area represent nearby support, with the 200-day moving average having tracked closer to the low $90s. A decisive close above $102.50 would signal that the market is pricing in near-certain completion plus meaningful CVR value, a necessary first step toward any sustained approach to $115.
Traders monitoring Lantheus and similar merger-driven names can supplement their research with Tickeron's AI Daily Buy/Sell Signals. This tool uses artificial intelligence to continuously scan thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on evolving market conditions, technical behavior, and AI-driven analysis. Investors can use these signals to surface new opportunities, keep tabs on existing positions, and identify shifting market trends more efficiently. For those navigating event-driven situations like Lantheus, automated signal monitoring can help flag turning points as new information emerges.
A move to $115 is possible but conditional. It is not a target Lantheus is likely to reach through ordinary trading momentum; instead, it depends almost entirely on the Curium acquisition closing and the market assigning substantial value to the contingent milestone payments. The strongest factors in favor are the firm cash consideration, a strong PYLARIFY franchise, and the presence of analysts who still see $115 as achievable. The primary risks are antitrust complications, deal timing, and the inherent uncertainty of CVR payouts that hinge on 2030 milestones. Investors should monitor regulatory updates, deal-progress disclosures, and any signals about how the market is valuing the CVRs, since these will determine whether $115 becomes reality.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor tells us that LNTH and ACET have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that LNTH and ACET's prices will move in lockstep.
| Ticker / NAME | Correlation To LNTH | 1D Price Change % | ||
|---|---|---|---|---|
| LNTH | 100% | -0.14% | ||
| ACET - LNTH | 32% Poorly correlated | -0.10% | ||
| VTRS - LNTH | 29% Poorly correlated | +0.79% | ||
| CRDL - LNTH | 27% Poorly correlated | +0.76% | ||
| SNDL - LNTH | 26% Poorly correlated | N/A | ||
| LFCR - LNTH | 24% Poorly correlated | +0.73% | ||
More | ||||
| Ticker / NAME | Correlation To LNTH | 1D Price Change % |
|---|---|---|
| LNTH | 100% | -0.14% |
| Pharmaceuticals: Generic industry (84 stocks) | 9% Poorly correlated | -0.05% |